4D Molecular Therapeutics FDMT

$ 7.18 -5.42%

Quarterly report 2024-Q3
added 11-13-2024

4D Molecular Therapeutics Financial Statements 2011-2024 | FDMT

Annual Financial Statements 4D Molecular Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	1.09 B	558 M	380 M	530 M	-	-	-	-	-	-	-	-	-
Shares	39.1 M	32.4 M	27.7 M	12.5 M	-	-	-	-	-	-	-	-	-
Historical Prices	28	17.2	13.7	42	-	-	-	-	-	-	-	-	-
Net Income	-101 M	-107 M	-71.3 M	-56.7 M	-49.3 M	-9.55 M	-11.2 M	-	-	-	-	-	-
Revenue	20.7 M	3.13 M	18 M	13.6 M	6.99 M	14.1 M	5.79 M	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	13.6 K	-	-	-	-	-	-	-	-	-
Operating Income	-113 M	-110 M	-71.3 M	-56.7 M	-50.8 M	-	-	-	-	-	-	-	-
Interest Expense	-181 K	-35 K	-121 K	-181 K	-46 K	-	-	-	-	-	-	-	-
EBITDA	-109 M	-108 M	-69.8 M	-55.2 M	-44.6 M	-9.7 M	-10.6 M	-	-	-	-	-	-
Operating Expenses	134 M	113 M	89.4 M	70.3 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	36.5 M	32.9 M	28 M	17.2 M	13.9 M	6.17 M	3.49 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement 4D Molecular Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	55.6 M	55.3 M	49.3 M	43.1 M	42.3 M	38.3 M	32.7 M	32.6 M	32.4 M	32.3 M	32.2 M	32.2 M	27 M	26.7 M	26.7 M	26.7 M	5.2 M	5.18 M	5.18 M	5.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-43.8 M	-35 M	-32.4 M	-	-10.3 M	-29.6 M	-28.7 M	-	-25.7 M	-28.1 M	-26.3 M	-	-22.2 M	-7.59 M	-16.4 M	-	-7.83 M	-15.2 M	-13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	3 K	5 K	28 K	-	20.2 M	239 K	298 K	-	500 K	162 K	1.22 M	-	1.37 M	14.6 M	2 M	-	7.42 M	3.63 M	3.54 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-51.1 M	-42.5 M	-38.1 M	-	-14 M	-32.1 M	-30.1 M	-	-26.5 M	-28.4 M	-26.4 M	-	-22.7 M	-7.6 M	-16.3 M	-	-7.82 M	-15.1 M	-13.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-1 K	-45 K	-10 K	-	-158 K	8 K	-19 K	-	9 K	-	-46 K	-	-13 K	-	-101 K	-	-21 K	-18 K	-13 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-49.9 M	-41.3 M	-37 M	-	-12.9 M	-31 M	-29.1 M	-	-26 M	-27.9 M	-26 M	-	-21.5 M	-6.84 M	-15.9 M	-	-6.74 M	-14.4 M	-12.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	51.1 M	42.5 M	38.2 M	-	34.2 M	32.4 M	30.4 M	-	27 M	28.6 M	27.6 M	-	24 M	22.2 M	18.3 M	-	15.2 M	18.8 M	16.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	12.7 M	10.6 M	10.3 M	-	9.11 M	8.79 M	7.99 M	-	8.06 M	8.17 M	8.23 M	-	8.19 M	6.95 M	5.54 M	-	3.68 M	3.06 M	3.65 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency